Globe Biotech Limited

Globe Biotech Secures First US Patent for Bangladesh with Single-Dose COVID-19 mRNA Vaccine

- Globe Biotech Limited has obtained the first US pharmaceutical patent in Bangladesh's 54-year history for its COVID-19 vaccine Bangavax, marking a significant milestone for the country's pharmaceutical industry. - Bangavax is the world's only single-dose mRNA vaccine effective against multiple COVID-19 variants, utilizing nanotechnology-based platform technology that can be adapted for other therapeutic applications. - The patent includes 30 invention claims covering the vaccine's nanotechnology platform and opens opportunities for Bangladesh to produce advanced vaccines domestically while reducing import dependency. - The achievement positions Bangladesh to leverage its scientific capabilities as it prepares for LDC graduation in 2026 and addresses challenges related to the Fourth Industrial Revolution.